Lisette Pregelj

Pongamia pinnata : An Untapped Resource for the Biofuels Industry of the Future

Pongamia pinnata (L.) Pierre is a fast-growing leguminous tree with the potential for high oil seed production and the added benefit of the ability to grow on marginal land. These properties support the suitability of this plant for large-scale vegetable oil production required by a sustainable biodiesel industry. The future success of P. pinnata as a sustainable source of feedstock for the biofuels industry is dependent on an extensive knowledge of the genetics, physiology and propagation of this legume. In particular, research should be targeted to maximizing plant growth as it relates to oil biosynthesis. This review assesses and integrates the biological, chemical and genetic attributes of the plant, providing the basis for future research into Pongamia’s role in an emerging industry.

Transcription profiling of the isoflavone phenylpropanoid pathway in soybean in response to Bradyrhizobium japonicum inoculation

Isoflavones are legume-specific secondary metabolites that function as defence compounds, signal molecules and regulators of gene expression during both pathogen attack and beneficial plant-microbe interactions. They are synthesised by a branch of the core phenylpropanoid pathway, using several isoenzymes within each enzymatic step. Gene-specific quantitative real-time reverse transcriptase PCR (qRT-PCR) was used to quantify expression of isoflavone synthesis genes in soybean (Glycine max L). Genes encoding chalcone synthase 7 (CHS7), chalcone synthase 8 (CHS8) and isoflavone synthase 1 (IFS1) displayed high basal expression levels in roots compared with hypocotyls, suggesting they could be the gene family members encoding the isoenzyme that contributes the most to the principal substrate flux towards specific isoflavone synthesis in roots. The genes encoding phenylalanine ammonia lyase 1 (PAL1) and IFS1 showed induction in root tissue after inoculation with Bradyrhizobium japonicum (Kirchner) Jordan, suggesting a control point. The absence of a functional nodulation regulator, GmNARK (G. max nodulation autoregulation receptor kinase), in the soybean mutant nts1007 resulted in significantly increased basal expression of PAL1 compared with levels induced by B. japonicum, suggesting that GmNARK is a negative regulator for isoflavone phenylpropanoid pathway genes during nodulation and that distinct genes, as opposed to the complete pathway, are coordinately regulated by the nodulation status of the mutant.

Changes in clinical trial length

This analysis of changes in the length of clinical trials over time provides evidence of increased efficiency in drug development and investigates the possible contributing factors.

Functional Genomics of the Regulation of Nodule Number in Legumes

Peter M. Gresshoff, Gustavo Gualtieri, Titeki Laniya, Arief Indrasumunar, Akira Miyahara, Sureeporn Nontachaiyapoom, Tim Wells, Bandana Biswas, Pick Kuen Chan, Paul Scott, M. Kinkema, M. Djordjevic, Dana Hoffmann, Lisette Pregelj, Diana M. Buzas, Dong Xi Li, Artem Men, Qunyi Jiang, Cheol-Ho Hwang and Bernard J. Carroll ARC Centre of Excellence for Integrative Legume Research; School of Life Sciences, and School of Molecular and Microbial Sciences and LAFS, The University of Queensland, St. Lucia, Brisbane QLD 4072, AGRF; Genome Interaction Group, RSBS, ANU, Canberra, ACT, Australia.

Trading-Off Innovation Speed for Knowledge During Drug Development

We investigate the impact of partnering on innovation speed, and trade-offs to knowledge accumulation. Using data on 20,819 clinical trials for new drug development commenced in the decade 2000-09, we show that while experience accumulated with partners has a greater effect on innovation speed than experience accumulated without partners, using more partners has a negative impact on the time it takes to complete trials. Further, firms that work alone experience shorter trials compared with firms that frequently partner. Yet, firms that work alone are less likely to expand later on into new therapeutic areas, which may limit their long-term capability to innovate. Contrary to extant claims in favor of open innovation, we conclude that firms need to manage the trade-offs between innovation speed, knowledge breadth, and information spillovers when making their decision to use partners in their clinical trials.